Clinical trials: Arrhythmias
Ventricular Fibrillation, Ventricular Tachycardia
Further Acute Research of a Subcutaneous Implantable Defibrillator (S-ICD) System
The purpose is to further evaluate the operation, safety, and feasibility of a subcutaneous implantable defibrillator (S-ICD) system in patients who require an implantable cardioverter defibrillator (ICD)for treating ventricular…
- Trial name
- NCT00399217
- Testing
- Subcutaneous Implantable Defibrillator (S-ICD) system, ICD
- Where
- United Kingdom
- Volunteers
- 55 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation
Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers
Primary objective was to evaluate the effects of dronedarone on Atrial Fibrillation (AF) burden (i.e. percent time in AF) as measured on electrogram (EGM) in subjects with a permanent pacemaker.
- Trial name
- HESTIA (NCT01135017)
- Testing
- Dronedarone
- Where
- 92 sites in United States
- Volunteers
- 112 people
- Sponsor
- Sanofi
Atrial Fibrillation
BAY59-7939 Japanese in Atrial Fibrillation (2nd)
This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).
- Trial name
- NCT00973323
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Warfarin
- Where
- 10 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Bayer
Atrial Fibrillation
Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
The main purpose of the study is to compare the mean AERP between treatment groups based on the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological remodeling resulting in a prolonged atrial…
- Trial name
- NCT00352560
- Testing
- Irbesartan
- Where
- 3 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in…
- Trial name
- CALLIPER (NCT03359876)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
- Where
- United States
- Volunteers
- 16,000 people
- Sponsor
- Bayer
Alzheimer's Disease
A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
The objective of this trial was to investigate the effect of galantamine (an acetylcholinesterase inhibitor) on heart rate and PR interval (the time it takes for the heart's electrical impulse to get from the atria to the…
- Trial name
- NCT00309725
- Testing
- galantamine
- Volunteers
- 139 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bradycardia, Heart Failure
BIO|CONCEPT.Amvia Study
The goal of this exploratory study is to test the preliminary safety and product performance of the new Amvia/Solvia pacemaker family in subjects that require a pacemaker or cardiac resynchronization therapy pacemaker (CRT-P)…
- Trial name
- NCT05610176
- Testing
- Amvia Sky pacemaker or CRT-P device
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 52 people
- Sponsor
- Biotronik Australia Pty Ltd.
Cardiac Arrhythmia
Safety and Efficacy of EasyCool Catheter
The goal of this observational study is to learn about risks and benefit of EasyCool Catheter for cardiovascular ablation in real-world patients suffering from cardiac arrythmias.
- Trial name
- NCT06482840
- Where
- Tunisia
- Volunteers
- 15 people
- Sponsor
- MedFact Engineering GmbH
Atrial Fibrillation
DURABLE-I Study: Dielectric Unravelling of Radiofrequency ABLation Effectiveness
The purpose of this study is to evaluate real-time gap detection using EPD D700 dielectric sensing compared with customary electrical isolation tests and Adenosine infusion at the end of the procedure.
- Trial name
- DURABLE-I (NCT02878213)
- Testing
- D700 System
- Where
- Russia
- Volunteers
- 39 people
- Sponsor
- EPD Solutions, A Philips Company
Atrial Fibrillation
Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically…
- Trial name
- NCT01370629
- Testing
- Vernakalant
- Where
- 6 sites in Austria, Denmark and 4 more
- Volunteers
- 2,015 people
- Sponsor
- Correvio International Sarl
Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
The study will evaluate the safety and 12-month effectiveness of the Pulmonary Vein Isolation plus Box Isolation of Fibrotic Areas (BIFA) ablation strategy with the Globe Pulsed Field System (Globe PF System) for the treatment of…
- Trial name
- GLOBAL-PF (NCT06973031)
- Testing
- Globe Pulsed Field System
- Where
- Germany
- Volunteers
- 115 people
- Sponsor
- Kardium Inc.
Bradycardia, Heart Failure
Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker Family
The study is designed as an open-label, prospective, international, multicenter, non-randomized study to determine safety and product performance of the CE-marked Amvia/Solvia pacemaker family, including the aATP, CRT AutoAdapt…
- Trial name
- NCT06018818
- Testing
- Amvia/Solvia pacemaker family
- Where
- 3 sites in Austria, Germany
- Volunteers
- 129 people
- Sponsor
- Biotronik SE & Co. KG
Tachycardia
Medtronic Market-Released DF4 Lead Imaging
The Medtronic Market-Released DF4 Lead Imaging Study is a prospective, non-randomized study, multi-center clinical investigation.
- Trial name
- NCT01626768
- Where
- 2 sites in Saudi Arabia, United Kingdom
- Volunteers
- 37 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Tachycardia, Ventricular, Heart Failure, Congestive
OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.
The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life…
- Conditions
- Tachycardia, Ventricular, Heart Failure, Congestive, Ventricular Fibrillation, Ventricular Dysfunction
- Trial name
- OMNI (NCT00277524)
- Where
- 113 sites in United States
- Volunteers
- 3,032 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Stroke, Atrial Fibrillation
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in…
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Trial name
- EngageAFTIMI48 (NCT00781391)
- Testing
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg)
- Where
- 1,009 sites in United States, Argentina and 44 more
- Volunteers
- 21,105 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation (AF), Stoke
Abbott Medical - VERITAS Study
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are…
- Trial name
- NCT06707688
- Testing
- Amulet™ 2 Left Atrial Appendage (LAA) Occluder
- Where
- 35 sites in United States, Belgium and 7 more
- Volunteers
- 458 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
The Validation of the FibriCheck Application for the Detection of Atrial Fibrillation
Optical sensing technologies have the potential to enable long-term heart rhythm monitoring. The medically certified and clinically validated FibriCheck technology has proven its value for spot-check measurements to detect AF.
- Trial name
- FLASH-AF (NCT03620656)
- Testing
- FibriCheck
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Qompium NV
Paroxysmal Atrial Fibrillation
A Single Arm Pilot Study of Pulsed Field Ablation in the Treatment of Paroxysmal Atrial Fibrillation
The objective of this pilot study is to confirm that endocardial ablation using the FARAPULSE Ablation System Plus with commercial design devices is both safe and effective for treating drug-resistant paroxysmal atrial…
- Trial name
- FARA-Free (NCT04474054)
- Testing
- Catheter ablation to treat paroxysmal atrial fibrillation
- Where
- Croatia
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation, Hypertension
Validation Study of an Advanced Blood Pressure Monitor
The proposed clinical study aims to validate the effectiveness of the WPM04 blood pressure monitor developed by Withings as a diagnostic tool for cardiovascular disorders.
- Conditions
- Atrial Fibrillation, Hypertension, Valvular Heart Disease
- Trial name
- TALISMAN (NCT04030494)
- Testing
- BP measurement, AF detection, VHD detection
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Withings
Atrial Fibrillation
A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
The primary purpose of this study is to evaluate the risk of major bleeding and stroke/systemic embolism (SE) among novel oral anti-coagulant (OAC) naïve and warfarin naïve Medicare Advantage patients with non-valvular atrial…
- Trial name
- NCT03189069
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Volunteers
- 36,000 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.